Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 2 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

2Total
Early P 1 (1)
P 2 (1)

Trial Status

Active Not Recruiting1
Not Yet Recruiting1

Clinical Trials (2)

Showing 2 of 2 trials
NCT07583810Phase 2Not Yet Recruiting

Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma

NCT03680586Early Phase 1Active Not RecruitingPrimary

Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma

Showing all 2 trials

Research Network

Activity Timeline